Get the Daily Brief
Latest Biotech News
Evolving Public Health and Policy Challenges Surrounding Vaccines and Regulatory Leadership
Tensions persist around vaccine policy and public health governance in the United States, marked by sharp divides between federal and state authorities. Recent upheavals within the Centers for...
FDA Adopts Real-Time Transparency: Unveils Drug Rejection Letters Publicly
The U.S. Food and Drug Administration (FDA) has initiated a groundbreaking policy to publish complete response letters (CRLs), commonly known as drug rejection letters, concurrently with their...
Novartis Bets Big: $200M Deal with Arrowhead for Parkinson’s RNA Therapy
Novartis has entered a significant partnership with Arrowhead Pharmaceuticals, investing $200 million upfront to license and develop RNA interference (RNAi) therapies targeting Parkinson’s disease...
Radiance Signs $1.165 Billion Deal for Bispecific ADC Targeting Solid Tumors
Radiance Biopharma, a relatively new biotech founded two years ago, has inked a global licensing agreement with Novatim Immune Therapeutics for a bispecific nanobody antibody-drug conjugate (ADC)...
Landmark Allogeneic CAR T Therapy for Progressive Multiple Sclerosis
Clinicians at the University of Nebraska’s Fred & Pamela Buffett Cancer Center administered a pioneering allogeneic CAR T-cell therapy, azercabtagene zapreleucel (azer-cel), to a 49-year-old...
Breakthroughs in High-Throughput Antibody Technology Accelerate Discovery
Researchers from the University of Illinois Urbana-Champaign unveiled oPool+ display, a revolutionary high-throughput platform that integrates oligo pool synthesis with mRNA display to rapidly...
Charm Therapeutics Raises $80 Million for Next-Gen Leukemia Menin Inhibitor
The London-based biotech Charm Therapeutics secured an $80 million Series B financing round, co-led by New Enterprise Associates and DR One, to push forward clinical development of its...
Regenxbio Reveals One-Year Data for Hunter Syndrome Gene Therapy Amid FDA Review
Regenxbio presented promising one-year follow-up data for its gene therapy targeting Hunter syndrome, a rare lysosomal storage disorder characterized by iduronate-2-sulfatase deficiency. The data,...
AI Enhances Bioprinting: Adaptive Volumetric Printing Integrates Imaging
Researchers from UMC Utrecht and Utrecht University developed GRACE, a cutting-edge volumetric bioprinting workflow combining artificial intelligence, advanced imaging, and context-aware printing....
Atlas Venture Raises $400M Opportunity Fund to Support Portfolio Biotechs
Atlas Venture, a prominent biotech investment firm, secured $400 million for its third Opportunity Fund dedicated to backing biopharma companies within its existing portfolio. This strategic...
FDA Vaccine Policy Turmoil: RFK Jr. Faces Senate Scrutiny Amid CDC Staff Exodus
U.S. Secretary of Health and Human Services Robert F. Kennedy Jr. confronted rigorous questioning and criticism during a Senate Finance Committee hearing focused on vaccine policy upheaval and...
Thermo Fisher Completes $4B Solventum Filtration Deal, Expands Life Sciences Segment
Thermo Fisher Scientific finalized its acquisition of Solventum's purification and filtration business for approximately $4.0 billion in cash, integrating it into the Life Sciences Solutions...
Octave Bioscience Raises $35.6M Series C Plus $15.5M Loan for Neurology Diagnostics
Octave Bioscience secured $35.6 million in Series C funding alongside a $15.5 million non-dilutive term loan from Silicon Valley Bank to advance its proteomic diagnostic tests. The company’s MSDA...
FDA Increases Transparency by Publishing Complete Response Letters for Drug Rejections
The Food and Drug Administration committed to enhanced transparency by releasing complete response letters (CRLs) to drugmakers shortly after issuance, including 89 previously undisclosed letters...
Atlas Venture Raises $400M Opportunity Fund to Support Portfolio Biotech Companies
Atlas Venture closed a $400 million Opportunity Fund aimed at supporting follow-on financing for its existing portfolio companies amid ongoing fundraising challenges in the biotech sector. The...
Treeline Biosciences Emerges with $1B Raised and Multiple Cancer Drug Candidates
Stealth-mode biotech Treeline Biosciences has revealed its first cancer drug candidates entering clinical trials and announced an additional $200 million in funding, accumulating over $1.1 billion...
BioNTech’s HER2 ADC Outperforms Roche’s Kadcyla in Phase 3 Breast Cancer Trial in China
BioNTech announced that its HER2-targeting antibody-drug conjugate achieved superior results over Roche's Kadcyla in a Phase 3 clinical trial conducted in China involving hard-to-treat breast...
Radiance Biopharma Signs $1.165B Deal for c-MET/EGFR Bispecific Nanobody ADC
Radiance Biopharma acquired global rights outside certain Asian markets for a bispecific nanobody antibody-drug conjugate targeting c-MET and EGFR to treat solid tumors, in a deal potentially...
Mechanism of Anemia in Bone Metastasis Unveiled by Princeton Researchers
Researchers at Princeton University and Rutgers Cancer Institute elucidated that anemia in patients with bone metastases stems from tumor cells hijacking specialized iron-transporting erythroblast...
CRISPR-Cas9 Functions as a Bacterial Defense Guardian Beyond Genome Editing
Research has uncovered a novel role of the CRISPR-Cas9 system, revealing that Cas9 acts as a guardian in bacterial immunity. Initially discovered in the early 2000s as a mechanism bacteria use to...